𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Long-term follow-up of cervical dystonia patients treated with botulinum toxin A

✍ Scribed by Peter Haussermann; Stefanie Marczoch; Christiane Klinger; Michael Landgrebe; Bastian Conrad; Andres Ceballos-Baumann

Publisher
John Wiley and Sons
Year
2004
Tongue
English
Weight
621 KB
Volume
19
Category
Article
ISSN
0885-3185

No coin nor oath required. For personal study only.

✦ Synopsis

Abstract

We followed the course in 100 consecutive patients with cervical dystonia (CD) after they were initially treated with botulinum toxin (BTX) in the form of Dysport 10 to 12 years ago. A total of 4 patients had died, and 6 were lost to follow‐up. Of the remaining 90 patients, 57 (63%) were still treated with BTX. In the patients treated at one centre over the whole period with Dysport, mean dose used during each treatment session was 833 (SD ± 339) units Dysport with a cumulative dose of 20,943 (SD ± 9462) units Dysport over a mean of 26.8 (SD ± 8.6) treatment cycles. Secondary nonresponse was detected in 3 of the 90 patients. During follow‐up, 12 patients developed blepharospasm, 13 oromandibular dystonia, and 17 patients writer's cramp. We conclude that BTX remains effective and safe for approximately 60% of CD patients for more than 10 years. © 2003 Movement Disorder Society

📜 SIMILAR VOLUMES

Long-term botulinum toxin treatment incr
Long-term botulinum toxin treatment increases employment rate in patients with cervical dystonia
✍ Inger Marie Skogseid; Jo Røislien; Bjørgulf Claussen; Emilia Kerty 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 153 KB

## Abstract We examined the impact of cervical dystonia (CD) and long‐term botulinum toxin (BTX) treatment on employment status. Data on employment status at onset of CD, at initiation of BTX treatment, and at evaluation of long‐term treatment were obtained from 62 CD patients aged 31–66 years (med

Long-term safety, efficacy, dosing, and
Long-term safety, efficacy, dosing, and development of resistance with botulinum toxin type B in cervical dystonia
✍ Brian Berman; Lauren Seeberger; Rajeev Kumar 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 64 KB

## Abstract Short‐term studies of cervical dystonia (CD) have demonstrated botulinum toxin type B (Bot B) to be safe and efficacious at doses of 5,000 to 10,000 units, but few long‐term studies have been published and the safety and efficacy of higher doses has not been established. Additionally, t

Long-term treatment with botulinum toxin
Long-term treatment with botulinum toxin type A in cervical dystonia has low immunogenicity by mouse protection assay
✍ Mitchell F. Brin; Cynthia L. Comella; Joseph Jankovic; Francis Lai; Markus Nauma 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 103 KB

## Abstract To evaluate the immunogenicity of botulinum toxin type A (BoNTA; BOTOX) in cervical dystonia (CD). Subjects diagnosed with CD for ≥1 year and previously naïve to BoNTs were treated with BoNTA in a prospective, open‐label, multicenter study. Serum samples were analyzed for BoNTA neutrali